Processa Pharmaceuticals, Inc.
PCSA
$1.99
-$0.17-7.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -4.32% | -17.97% | -14.46% | -12.21% | -26.00% |
| Total Depreciation and Amortization | 9.09% | 33.33% | 71.43% | 140.00% | 175.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 60.16% | -30.84% | -11.64% | 20.25% | 3.34% |
| Change in Net Operating Assets | -88.78% | 276.83% | 1,473.93% | 395.22% | 760.73% |
| Cash from Operations | -10.33% | -2.68% | -1.25% | 3.50% | -16.93% |
| Capital Expenditure | -- | -- | -- | 100.00% | -14.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -36,275.00% | -42,087.50% | -26,462.50% | 100.00% | -14.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 33.33% | 12.07% | -26.92% | -118.92% | -147.83% |
| Issuance of Common Stock | -47.72% | 109.56% | 113.80% | 96.41% | 94.82% |
| Repurchase of Common Stock | 97.92% | -25.68% | 57.55% | 80.47% | 86.13% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -47.66% | 109.79% | 114.40% | 97.75% | 97.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -593.65% | 79.98% | 223.63% | 186.09% | 143.96% |